News

Antibody deal with Janssen
Enlarge image

GenmabDenmark

Antibody deal with Janssen

17.07.2012 - When it comes to bispecific antibodies Genmab’s Duobody technology is becoming more and more popular, with Janssen Biotech now also reliant on it.

Danish Genmab A/S received an upfront payment of US$3,5m (DKK21m) from Janssen Biotech, Inc. – a Johnson & Johnson company from Horsham, Pennsylvania (USA). In return Genmab will create up to 10 panels for bispecific antibody production using its close to gold standard platform Duobody technology. No further details concerning the targeted diseases were revealed. All research will be fully funded by Janssen. Milestone and license payments of up to US$175m (DKK1.062m) for each product are additionally expected revenues – as are royalties on any product which will be commercialised.

After an unnamed pharmaceutical partner last December and Novartis last month, the Janssen deal is already the third and so far biggest agreement that Genmab could wrap up. The press announcement’s tone was therefore pretty confident: „Since the introduction of our Duobody platform in 2010, we have believed in its potential to become the preferred technology for next generation bispecific antibody therapeutics. Today's announcement is another indicator that the pharmaceutical industry recognises our leadership in the therapeutic antibody field“, said Jan van de Winkel, Chief Executive Officer of Genmab.

The Copenhagen company also stated that the deal likely will not have any material impact on its 2012 financial guidance.

http://www.european-biotechnology-news.com/news/news/2012-03/genmabs-golden-cash-cow.html

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • KAROLINSKA (S)7.85 SEK9.03%

FLOP

  • IMMUPHARMA (UK)26.50 GBP-10.17%
  • DBV TECHNOLOGIES (F)53.40 EUR-5.79%
  • FLAMEL TECHNOLOGIES (F)11.37 USD-4.29%

TOP

  • BIOFRONTERA (D)3.26 EUR39.3%
  • SYNAIRGEN (UK)35.50 GBP36.5%
  • SWEDISH ORPHAN BIOVITRUM (S)15.24 USD27.5%

FLOP

  • EVOCUTIS (UK)0.05 GBP-28.6%
  • THERAMETRICS (CH)0.03 CHF-25.0%
  • OREXO (S)47.10 SEK-22.1%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.40 SEK1818.9%
  • NICOX (F)8.01 EUR321.6%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.7%
  • BB BIOTECH (D)44.01 EUR-83.2%
  • CYTOS (CH)0.25 CHF-78.6%

No liability assumed, Date: 05.05.2016